← 返回

单细胞 RNA 测序时代的癌症免疫治疗:精准医学视角

英文原题:Immunotherapy of cancer in single-cell RNA sequencing era: A precision medicine perspective.

查看英文原题

Immunotherapy of cancer in single-cell RNA sequencing era: A precision medicine perspective.

PubMed 2021/12/22(内容时间) Biomed Pharmacother

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

免疫治疗已经彻底改变了癌症治疗,并为肿瘤免疫学带来了新的方向。有效的免疫治疗需要采用合适的靶抗原,优化抗原肽、APC与T细胞之间的相互作用,并同时抑制那些抑制免疫治疗效果并导致耐药性的负调控过程。肿瘤异质性及其微环境是患者产生耐药性的主要原因。近年来,随着单细胞RNA测序技术的出现及其与免疫治疗的结合,我们现在可以通过检测免疫检查点的转录活性、筛选高转录水平的新抗原、识别稀有细胞以及其他重要过程,在单细胞分辨率下具体评估肿瘤面对免疫治疗药物时的机制。本综述聚焦于scRNA-seq,尤其是其在癌症免疫治疗中的应用。

展开英文摘要原文

Immunotherapy has revolutionized cancer treatment and brought new aspects into tumor immunology. Effective immunotherapy will require using the suitable target antigens, optimizing the interaction between the antigenic peptide, the APC, and the T cell, and the simultaneous inhibitor of the negative regulatory process that inhibits immunotherapeutic effects and develop resistance. Tumor heterogeneity and its microenvironment is the leading cause of resistance in patients.

Recently by emerging the single-cell RNA sequencing technology and its combination with immunotherapy, now we can specifically evaluate the mechanism of tumors in the face of immunotherapy agents at the single-cell resolution by detecting the transcriptional activity of immune checkpoints, screening neoantigens with high transcription levels, identifying rare cells, and other important processes. This review focuses on scRNA-seq, particularly on its application in cancer immunotherapy.

论文信息

作者
Erfanian N、Derakhshani A、Nasseri S、Fereidouni M、Baradaran B、Jalili Tabrizi N、Brunetti O、Bernardini R
第一作者单位
Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran.Iran
通讯作者单位
Cellular & Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran. Electronic address: H.safarpour@bums.ac.ir.Iran
文献类型
综述
期刊
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2022 Feb
原文标识
PubMed 34953396 · DOI 10.1016/j.biopha.2021.112558